Evidence map›Paper›PMID 19263515›Full record

ArticleCellular signalling2009

Integrated modulation of phorbol ester-induced Raf activation in EL4 lymphoma cells.

Shujie Han, Kathryn E Meier

Abstract read
In one paragraph

Article in Cellular signalling, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Inhibition of RAF dimers: it takes two to tango.Biochemical Society transactions · 2021
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shujie HanDepartment of Pharmaceutical Sciences, Washington State University, Pullman, Washington 99164-6534, United States.
Kathryn E Meier
Washington State University · US

Funding

Phorbol Ester Response and Resistance in Thymoma CellsR01CA094144 · NCI · WASHINGTON STATE UNIVERSITY · PI MEIER, KATHRYN E · 2004 to 2008
$1.2M
NCI NIH HHS CA094144-01NCI NIH HHS R01 CA094144
6 · The paper itself

Abstract

The EL4 murine lymphoma cell line exists in variant phenotypes that differ with respect to responses to the tumor promoter phorbol 12-myristate 13-acetate (PMA1). Previous work showed that "PMA-sensitive" cells, characterized by a high magnitude of PMA-induced Erk activation, express RasGRP, a phorbol ester receptor that directly activates Ras. In "PMA-resistant" and "intermediate" EL4 cell lines, PMA induces Erk activation to lesser extents, but with a greater response in intermediate cells. In the current study, these cell lines were used to examine mechanisms of Raf-1 modulation. Phospho-specific antibodies were utilized to define patterns and kinetics of Raf-1 phosphorylation on several sites. Further studies showed that Akt is constitutively activated to a greater extent in PMA-resistant than in PMA-sensitive cells, and also to a greater extent in resistant than intermediate cells. Akt negatively regulates Raf-1 activation (Ser259), partially explaining the difference between resistant and intermediate cells. Erk activation exerts negative feedback on Raf-1 (Ser289/296/301), thus resulting in earlier termination of the signal in cells with a higher level of Erk activation. RKIP, a Raf inhibitory protein, is expressed at higher levels in resistant cells than in sensitive or intermediate cells. Knockdown of RKIP increases Erk activation and also negative feedback. In conclusion, this study delineates Raf-1 phosphorylation events occurring in response to PMA in cell lines with different extents of Erk activation. Variations in the levels of expression and activation of multiple signaling proteins work in an integrated fashion to modulate the extent and duration of Erk activation.

Indexed as

AnimalsCell Line, TumorExtracellular Signal-Regulated MAP KinasesGene Knockdown TechniquesKineticsLymphomaMicePhosphatidylethanolamine Binding ProteinPhosphorylationProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-rafRNA, Small InterferingTetradecanoylphorbol Acetate4-O-methyl-12-O-tetradecanoylphorbol 13-acetateExtracellular Signal-Regulated MAP KinasesPhosphatidylethanolamine Binding ProteinProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-rafRaf kinase inhibitory protein, mouseRNA, Small InterferingTetradecanoylphorbol Acetate

Identifiers

PMID19263515
PMCPMC2652690
OpenAlexW2055829374

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.